Drug Evaluation

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Korea

Search for more papers by this author

Yeon Hee Park

*Author for correspondence: Tel.: +82 2 3410 1780;

E-mail Address: yeonh.park@samsung.com

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Korea

Search for more papers by this author

Published Online:26 Nov 2021https://doi.org/10.2217/fon-2021-0550

View article

Abstract

Trastuzumab deruxtecan (T-DXd, DS-8201), an anti-HER2 antibody–drug conjugate, has shown significant clinical benefits in HER2+ metastatic breast cancer patients. In the phase 2 DESTINY-Breast01 trial, T-DXd demonstrated an objective response of 60.9% and median progression-free survival of 16.4 months, laying the foundation for accelerated approval in HER2+ metastatic breast cancer patients who have received two or more prior anti-HER2-based regimens in the metastatic setting. Moreover, T-DXd exhibited promising antitumor efficacy against HER2-low-expressing metastatic breast cancer. Its distinctive side effect was pneumonitis, with a 13.6% incidence. It is approved in the US with boxed warnings for interstitial lung disease and embryo–fetal toxicity. This review focuses on preclinical, pharmacokinetic and pharmacodynamic data on T-DXd and clinical evidence of its antitumor activity (both as monotherapy and in combination) and tolerability in metastatic breast cancer.

Lay abstract

Breast cancer can be grouped based on its HR and HER2 status. For patients with HER2+ breast cancer, treatments that fight HER2 portion are adopted. Trastuzumab deruxtecan (DS-8201) is a new drug that consists of two parts: a cytotoxic drug and anti-HER2 antibody. It can selectively target HER2-expressing tumor cells. In a recent clinical trial, trastuzumab deruxtecan demonstrated tumor shrinkage in six of ten patients. The time to increase in tumor size or death was 16 months. Its antitumor effect was also demonstrated in low-HER2-expressing breast cancer. Approximately 13% of patients experience lung inflammation following trastuzumab deruxtecan treatment. In these cases, the drug should be promptly halted and the doctor can start steroid therapy.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 28(9), 963–968 (2010).
MedlineGoogle Scholar
2. Giannone G, Montemurro F. A new player in the treatment of HER2+ tumours. Lancet Oncol. 20(6), 748–750 (2019).
MedlineGoogle Scholar
3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast cancer. Ver3.2021 (2021). www.nccn.org
Google Scholar
4. Giordano SH, Temin S, Chandarlapaty S et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 36(26), 2736–2740 (2018).
MedlineGoogle Scholar
5. Murthy RK, Loi S, Okines A et al. Tucatinib, trastuzumab, and capecitabine for HER2+ metastatic breast cancer. N. Engl. J. Med. 382(7), 597–609 (2020).
Medline CASGoogle Scholar
6. Shah M, Wedam S, Cheng J et al. FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2+ breast cancer. Clin. Cancer Res. 27(5), 1220–1226 (2021).
Medline CASGoogle Scholar
7. Corti C, Criscitiello C. Tucatinib approval by EMA expands options for HER2+ locally advanced or metastatic breast cancer. ESMO Open 6(2), 100063 (2021).
Medline CASGoogle Scholar
8. FDA approves neratinib for metastatic HER2+ breast cancer (2021). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer
Google Scholar
9. Saura C, Oliveira M, Feng YH et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA Trial. J. Clin. Oncol. 38(27), 3138–3149 (2020).
Medline CASGoogle Scholar
10. Bang YJ, Giaccone G, Im SA et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2+ advanced solid tumors. Ann. Oncol. 28(4), 855–861 (2017).
Medline CASGoogle Scholar
11. Rugo HS, Im SA, Cardoso F et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 7(4), 573–584 (2021).
MedlineGoogle Scholar
12. FDA approves margetuximab for metastatic HER2+ breast cancer (2021). www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer
Google Scholar
13. Kim TM, Lee K-W, Oh D-Y et al. Phase 1 studies of poziotinib, an irreversible pan-HER tyrosine kinase inhibitor in patients with advanced solid tumors. Cancer Res. Treat. 50(3), 835–842 (2018).
Medline CASGoogle Scholar
14. Im SA, Kim JH, Lee KH et al. Abstract P4-13-19: poziotinib, an oral, irreversible pan-HER inhibitor, demonstrates promising clinical activity in metastatic HER2 positive breast cancer patients. Cancer Res. 76(Suppl. 4), P4-13-19 (2016).
Google Scholar
15. Park YH, Lee KH, Sohn J et al. A phase II trial of pan-HER inhibitor poziotinib, in patients with HER2+ metastatic breast cancer who have received at least two prior HER2-directed regimens: the results of NOV120101-203 trial. Ann. Oncol. 28, v74 (2017).
Google Scholar
16. Park YH, Lee KH, Sohn JH et al. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2+ metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. Int. J. Cancer 143(12), 3240–3247 (2018).
Medline CASGoogle Scholar
17. Kim J-Y, Lee E, Park K et al. Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2+ breast cancer patients. Int. J. Cancer 145(6), 1669–1678 (2019).
Medline CASGoogle Scholar
18. Xu B, Yan M, Ma F et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2+ metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22(3), 351–360 (2021).
Medline CASGoogle Scholar
19. Aftimos P, Van Herpen C, Mommers E et al. Abstract P6-12-02: SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2+ and HER2-negative metastatic breast cancer. Cancer Res. 77(Suppl. 4), P6-12-02 (2017).
Google Scholar
20. Saura C, Thistlethwaite F, Banerji U et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2+ or HER2-low metastatic breast cancer. J. Clin. Oncol. 36(Suppl. 15), 1014 (2018).
Google Scholar
21. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107(7), 1039–1046 (2016). • This study investigated the bystander killing effect of trastuzumab deruxtecan, the mechanism behind its activity against HER2-low-expressing tumors.
Medline CASGoogle Scholar
22. Tsurutani J, Iwata H, Krop I et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple advanced solid tumors. Cancer Discov. 10(5), 688–701 (2020).
Medline CASGoogle Scholar
23. Nguyen X, Hooper M, Borlagdan JP, Palumbo A. A review of fam-trastuzumab deruxtecan-nxki in HER2+ breast cancer. Ann. Pharmacother. 55(11), 1410–1418 (2021).
Medline CASGoogle Scholar
24. Ogitani Y, Aida T, Hagihara K et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22(20), 5097–5108 (2016). • This preclinical study demonstrated antitumor responses, pharmakokinetics and safety profiles of trastuzumab deruxtecan in cell and animal models.
Medline CASGoogle Scholar
25. Rinnerthaler G, Gampenrieder SP, Greil R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int. J. Mol. Sci. 20(5), 5 (2019).
Google Scholar
26. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem. Pharm. Bull (Tokyo) 67(3), 173–185 (2019).
Medline CASGoogle Scholar
27. Poon KA, Flagella K, Beyer J et al. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol. Appl. Pharmacol. 273(2), 298–313 (2013).
Medline CASGoogle Scholar
28. Doi T, Shitara K, Naito Y et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 18(11), 1512–1522 (2017).
Medline CASGoogle Scholar
29. Nagai Y, Oitate M, Shiozawa H, Ando O. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, in cynomolgus monkeys. Xenobiotica 49(9), 1086–1096 (2019).
Medline CASGoogle Scholar
30. Andrikopoulou A, Zografos E, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer. Clin. Breast Cancer 21(3), e212–e219 (2021).
Medline CASGoogle Scholar
31. Tamura K, Tsurutani J, Takahashi S et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2+ breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 20(6), 816–826 (2019). •• This phase I study demonstrated antitumor response of trastuzumab deruxtecan in both HER2+ and HER2-low-expressing breast cancer patients.
Medline CASGoogle Scholar
32. Mckenzie JA, Mbofung RM, Malu S et al. The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy. J. Natl Cancer Inst. 110(7), 777–786 (2018).
MedlineGoogle Scholar
33. Hamilton E, Shapiro CL, Petrylak D et al. Abstract PD3-07: trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study. Cancer Res. 81(Suppl. 4), PD3-07–PD03-07 (2021).
Google Scholar
34. Modi S, Saura C, Yamashita T et al. Trastuzumab deruxtecan in previously treated HER2+ breast cancer. N. Engl. J. Med. 382(7), 610–621 (2020). •• This phase II study demonstrated antitumor response of trastuzumab deruxtecan in patients with HER2+ breast cancer.
Medline CASGoogle Scholar
35. Takahashi S, Modi S, Tsurutani J et al. Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2+ breast cancer. Ann. Oncol. 30, vi84 (2019).
Google Scholar
36. Modi S, Saura C, Yamashita T et al. Abstract PD3-06: updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. Cancer Res. 81(Suppl. 4), PD3-06–PD03-06 (2021).
Google Scholar
37. Jerusalem GHM, Park YH, Yamashita T et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: a subgroup analysis of the DESTINY-Breast01 trial. J. Clin. Oncol. 39(Suppl. 15), 526 (2021).
Google Scholar
38. Jerusalem G, Park YH, Yamashita T et al. 138O CNS metastases in HER2+ metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses. Ann. Oncol. 31, S63–S64 (2020).
Google Scholar
39. Shitara K, Iwata H, Takahashi S et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2+ gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 20(6), 827–836 (2019).
Medline CASGoogle Scholar
40. Shitara K, Bang Y-J, Iwasa S et al. Trastuzumab deruxtecan in previously treated HER2+ gastric cancer. N. Engl. J. Med. 382(25), 2419–2430 (2020).
Medline CASGoogle Scholar
41. Tsurutani J, Iwata H, Krop I et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discovery 10(5), 688–701 (2020).
Medline CASGoogle Scholar
42. DS8201a and pembrolizumab in participants with locally advanced/metastatic breast or non-small cell lung cancer (2021). https://clinicaltrials.gov/ct2/show/NCT04042701
Google Scholar
43. A study of novel anti-cancer agents in patients with metastatic triple negative breast cancer (BEGONIA) (2021). https://clinicaltrials.gov/ct2/show/NCT03742102
Google Scholar
44. Hackshaw MD, Danysh HE, Singh J et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2+ metastatic breast cancer. Breast Cancer Res. Treat. 183(1), 23–39 (2020).
Medline CASGoogle Scholar
45. Kumagai K, Aida T, Tsuchiya Y, Kishino Y, Kai K, Mori K. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 111(12), 4636–4645 (2020).
Medline CASGoogle Scholar
46. Fehrenbacher L, Cecchini RS, Geyer CE Jr et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J. Clin. Oncol. 38(5), 444–453 (2020).
Medline CASGoogle Scholar
47. Gianni L, Lladó A, Bianchi G et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28(7), 1131–1137 (2010).
Medline CASGoogle Scholar
48. Yazaki S, Hashimoto J, Ogita S, Nakano E, Yamauchi T. Lower response to T-DM1 in metastatic breast cancer patients with HER2 IHC score of 2 and FISH positive compared with IHC score of 3. Ann. Oncol. 28, v102–v103 (2017).
Google Scholar
49. Brufsky A, Zulfiqar M, Peguero J, Lathrop K, Bhat G, Lebel F. Abstract PD1-07: a phase 2 study of poziotinib in patients with HER2+ metastatic breast cancer heavily pre-treated with HER2-targeted therapy. Cancer Res. 81(Suppl. 4), PD1-07–PD01-07 (2021).
Google Scholar
50. A phase 1b study of T-DXd combinations in HER2-low advanced or metastatic breast cancer (DB-08) (2021). https://clinicaltrials.gov/ct2/show/NCT04556773
Google Scholar
51. Trastuzumab deruxtecan in participants with HER2-mutated metastatic non-small cell lung cancer (NSCLC) (DESTINY-LUNG02) (2021). https://clinicaltrials.gov/ct2/show/NCT04644237?term=trastuzumab+deruxtecan&draw=2&rank=1
Google Scholar
52. Trastuzumab deruxtecan for subjects with HER2+ gastric cancer or gastro-esophageal junction adenocarcinoma after progression on or after a trastuzumab-containing regimen (DESTINY-Gastric04). (2021) https://clinicaltrials.gov/ct2/show/NCT04704934?term=trastuzumab+deruxtecan&draw=2&rank=3
Google Scholar
53. Trastuzumab deruxtecan in participants with HER2-overexpressing advanced or metastatic colorectal cancer (DESTINY-CRC02) (2021). https://clinicaltrials.gov/ct2/show/NCT04744831?term=trastuzumab+deruxtecan&draw=3&rank=13
Google Scholar
54. Trastuzumab deruxtecan for the treatment of HER2+ newly diagnosed or recurrent osteosarcoma (2021). https://clinicaltrials.gov/ct2/show/NCT04616560?term=trastuzumab+deruxtecan&draw=2&rank=8
Google Scholar
55. A phase 1b/2 study of T-DXd combinations in HER2+ metastatic breast cancer (DB-07) (2021). https://clinicaltrials.gov/ct2/show/NCT04538742
Google Scholar
56. Trastuzumab deruxtecan alone or in combination with anastrozole for the treatment of early stage HER2 low, hormone receptor positive breast cancer (2021). https://clinicaltrials.gov/ct2/show/NCT04553770
Google Scholar
57. Trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2+ metastatic breast cancer (DESTINY-Breast09) (2021). https://clinicaltrials.gov/ct2/show/NCT04784715
Google Scholar
58. Andre F, Hamilton EP, Loi S et al. Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2+ advanced or metastatic breast cancer: a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07). J. Clin. Oncol. 39(Suppl. 15), TPS1096–TPS1096 (2021).
Google Scholar
59. DS-8201a for treatment of aBc, BRain Mets, and Her2[+] disease (DEBBRAH) (2021). https://clinicaltrials.gov/ct2/show/NCT04420598?term=trastuzumab+deruxtecan&draw=3&rank=15
Google Scholar
60. FDA approves fam-trastuzumab deruxtecan-nxki for HER2+ gastric adenocarcinomas (2021). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas
Google Scholar
61. DS-8201a in pre-treated HER2 breast cancer that cannot be surgically removed or has spread [DESTINY-Breast02] (2021). www.clinicaltrials.gov/ct2/show/NCT03523585
Google Scholar
62. DS-8201a versus T-DM1 for human epidermal growth factor receptor 2 (HER2)-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab and taxane [DESTINY-Breast03] (2021) https://www.clinicaltrials.gov/ct2/show/NCT03529110
Google Scholar
63. Trastuzumab deruxtecan (DS-8201a) versus investigator's choice for HER2-low breast cancer that has spread or cannot be surgically removed [DESTINY-Breast04] (2021). https://clinicaltrials.gov/ct2/show/NCT03734029
Google Scholar
64. A study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in high-risk HER2+ participants with residual invasive breast cancer following neoadjuvant therapy (DESTINY-Breast05) (2021). https://clinicaltrials.gov/ct2/show/NCT04622319
Google Scholar
65. Study of trastuzumab deruxtecan (T-DXd) vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer (DB-06) (2021). https://clinicaltrials.gov/ct2/show/NCT04494425
Google Scholar
66. A study of tucatinib plus trastuzumab deruxtecan in HER2+ breast cancer (HER2CLIMB-04) (2021). https://clinicaltrials.gov/ct2/show/NCT04539938
Google Scholar

Vol. 18, No. 1

Metrics

Downloaded 1,268 times

History

Received 3 May 2021

Accepted 22 October 2021

Published online 26 November 2021

Published in print January 2022

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

Company review disclosure

In addition to the peer-review process, with the authors' consent, the manufacturer of the product discussed in this article was given the opportunity to review the manuscript for factual accuracy. Changes were made by the authors at their discretion and based on scientific or editorial merit only. The authors maintained full control over the manuscript, including content, wording and conclusions.

PDF download

Trastuzumab deruxtecan for HER2+ advanced breast cancer

Abstract

Lay abstract

References